Merck KGaA of Germany has decided to discontinue the clinical development of the immunotherapy tecemotide in non-small cell lung cancer following the failure of a Japanese study to show effectiveness on any trial endpoint.
Eli Lilly and Company said the results of a Phase 3 study of its antibody treatment Cyramza (ramucirumab), which has already been approved for advanced gastric cancer, met its primary endpoint of overall survival in patients with metastatic colorectal cancer.
Data from two Phase 3 studies of the antibody mepolizumab in severe asthma have shown statistically significant reductions in asthma exacerbations and a reduction in the need for daily oral corticosteroid use, according to the developer, GlaxoSmithKline Plc.
Alizé Pharma SAS has raised €5 million to finance further development of an analog of a metabolic hormone that has the potential to treat type-2 diabetes and a rare children’s disease called the Prader-Willi syndrome.
Results of a Phase 2 study of benralizumab from AstraZeneca Plc for chronic obstructive pulmonary disease (COPD) have been published in The Lancet Respiratory Medicine. The drug is said to be the first biologic to show a marked reduction in inflammation.
Novartis is planning regulatory submissions in both the US and Europe for a new heart drug in the wake of trial results showing the drug's superior performance to enalapril, a standard treatment for hypertension and heart failure.
Fresh from a successful European initial public share offering, the Belgian antibody developer ArGEN-X NV has given an update on the progress of its two lead products directed at potential cancer indications.
A Phase 3 trial of the cancer drug Kyprolis administered as a single agent for patients with refractory multiple myeloma has failed to meet its endpoint of improving overall survival. This follows another study of the same drug in combination with two other agents that was positive.
A first human study of a monoclonal antibody targeting the toll-like receptor 4 for the potential treatment of rheumatoid arthritis has been shown to be safe and well tolerated, according to the developer Novimmune SA of Switzerland.
A Phase 3 trial of a new combination treatment for relapsed multiple myeloma reached its primary endpoint of progression-free survival, demonstrating that carfilzomib with two other agents helped patients live 8.7 months longer without their disease worsening, Amgen announced.